rct
    2023
    High Quality

    Nicotinamide for skin-cancer chemoprevention in transplant recipients (ONTRANS): a randomized trial

    Allen NC, Martin AJ, Snaidr VA

    Published in New England Journal of Medicine

    Key Findings

    Nicotinamide did not reduce new keratinocyte carcinomas in organ transplant recipients over 12 months.

    Conclusions

    Well-powered null result in immunosuppressed patients.

    Limitations

    Population differs from immunocompetent trials.

    Supplements Studied

    Nicotinamide did not reduce new keratinocyte carcinomas in organ transplant recipients.

    Vitamin B3
    Vitamin

    Nicotinamide did not reduce new keratinocyte carcinomas in organ transplant recipients over 12 months.

    Related Health Concerns

    Cancer

    Study Details

    Year:2023
    Sample Size:158
    Duration:52 weeks
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.